0001140361-14-014134.txt : 20140325
0001140361-14-014134.hdr.sgml : 20140325
20140325181027
ACCESSION NUMBER: 0001140361-14-014134
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140321
FILED AS OF DATE: 20140325
DATE AS OF CHANGE: 20140325
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER RD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591-6707
BUSINESS PHONE: 9143477000
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sanofi
CENTRAL INDEX KEY: 0001121404
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: I0
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 14717000
BUSINESS ADDRESS:
STREET 1: 54 RUE LA BOETIE
CITY: PARIS
STATE: I0
ZIP: 75008
BUSINESS PHONE: 33153774400
MAIL ADDRESS:
STREET 1: 54 RUE LA BOETIE
CITY: PARIS
STATE: I0
ZIP: 75008
FORMER NAME:
FORMER CONFORMED NAME: SANOFI-AVENTIS
DATE OF NAME CHANGE: 20040826
FORMER NAME:
FORMER CONFORMED NAME: SANOFI SYNTHELABO SA
DATE OF NAME CHANGE: 20010104
4
1
doc1.xml
FORM 4
X0306
4
2014-03-21
0
0000872589
REGENERON PHARMACEUTICALS INC
REGN
0001121404
Sanofi
54 RUE LA BOETIE
PARIS
I0
75008
FRANCE
0
0
1
0
Common Stock
2014-03-21
4
P
0
5024
313.1237
A
18183274
I
See note
Common Stock
2014-03-21
4
P
0
10934
314.2130
A
18194208
I
See note
Common Stock
2014-03-21
4
P
0
14463
315.0737
A
18208671
I
See note
Common Stock
2014-03-21
4
P
0
5700
316.1587
A
18214371
I
See note
Common Stock
2014-03-21
4
P
0
23644
317.2291
A
18238015
I
See note
Common Stock
2014-03-21
4
P
0
26229
318.3630
A
18264244
I
See note
Common Stock
2014-03-21
4
P
0
37436
319.1846
A
18301680
I
See note
Common Stock
2014-03-21
4
P
0
23411
320.0872
A
18325091
I
See note
Common Stock
2014-03-21
4
P
0
16036
321.2298
A
18341127
I
See note
Common Stock
2014-03-21
4
P
0
21101
322.2800
A
18362228
I
See note
Common Stock
2014-03-21
4
P
0
27688
323.3238
A
18389916
I
See note
Common Stock
2014-03-21
4
P
0
31754
324.0934
A
18421670
I
See note
Common Stock
2014-03-21
4
P
0
25116
325.1870
A
18446786
I
See note
Common Stock
2014-03-21
4
P
0
13905
326.1081
A
18460691
I
See note
Common Stock
2014-03-21
4
P
0
8918
327.0443
A
18469609
I
See note
Common Stock
2014-03-21
4
P
0
7476
328.2175
A
18477085
I
See note
Common Stock
2014-03-21
4
P
0
1749
329.1682
A
18478834
I
See note
Common Stock
2014-03-21
4
P
0
506
330.3839
A
18479340
I
See note
Common Stock
2014-03-21
4
P
0
2110
331.4914
A
18481450
I
See note
Common Stock
2014-03-21
4
P
0
1915
332.7833
A
18483365
I
See note
The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN").
Purchase prices range from $312.50 to $313.49 per share, inclusive.
Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 15,683,813 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuers Board of Directors.
Purchase prices range from $313.59 to $314.58 per share, inclusive.
Purchase prices range from $314.59 to $315.55 per share, inclusive.
Purchase prices range from $315.69 to $316.65 per share, inclusive.
Purchase prices range from $316.71 to $317.70 per share, inclusive.
Purchase prices range from $317.72 to $318.71 per share, inclusive.
Purchase prices range from $318.72 to $319.71 per share, inclusive.
Purchase prices range from $319.72 to $320.71 per share, inclusive.
Purchase prices range from $320.75 to $321.74 per share, inclusive.
Purchase prices range from $321.75 to $322.70 per share, inclusive.
Purchase prices range from $322.75 to $323.74 per share, inclusive.
Purchase prices range from $323.75 to $324.73 per share, inclusive.
Purchase prices range from $324.75 to $325.73 per share, inclusive.
Purchase prices range from $325.75 to $326.68 per share, inclusive.
Purchase prices range from $326.78 to $327.60 per share, inclusive.
Purchase prices range from $327.79 to $328.77 per share, inclusive.
Purchase prices range from $328.82 to $329.61 per share, inclusive.
Purchase prices range from $330.00 to $330.76 per share, inclusive.
Purchase prices range from $331.05 to $331.99 per share, inclusive.
Purchase prices range from $332.39 to $333.00 per share, inclusive.
Due to technical limitation of the number of transactions reported, this report is 1 of 2.
/s/ John Felitti, Associate Vice President, Corporate Law, Financial & Securities Law
2014-03-25